sulfasalazine / Generic mfg. - LARVOL DELTA

MANAGEMENT CHALLENGES IN MEDULLARY SPONGE KIDNEY COMPLICATED BY RHEUMATOID ARTHRITIS AND RECURRENT URINARY TRACT INFECTIONS: A CASE REPORT (ISN-WCN 2026) - "Management becomes challenging when immunosuppression, antimicrobial resistance, and drug allergies limit therapeutic options.Methods A woman in her 60s with rheumatoid arthritis, controlled on sulfasalazine 1,000 mg/day and subcutaneous tocilizumab 162 mg every 2 weeks, was diagnosed with MSK in her 40s after pyelonephritis and diffuse medullary calcifications on non-contrast CT...Urine cultures repeatedly yielded multidrug-resistant Escherichia coli resistant to ampicillin, levofloxacin, and trimethoprim–sulfamethoxazole...Joint symptoms remained under control following the single tocilizumab dose.Conclusion In cases of MSK complicated by immunosuppression, recurrent UTIs may require tailored, stepwise regimens and careful antimicrobial stewardship when resistance and allergies constrain options. A strategic selection and sequencing of agents, including cephalexin (dosage adjusted for body weight), gentamicin, and fosfomycin calcium 9 g/day, was instrumental in..."

Case report • Clinical • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Pain • Nephrology • Rheumatoid Arthritis • Rheumatology

The effect of individual sulfasalazine administration and in combination with esomeprazole on buccal mucosa of albino rats: histological, immunohistochemical, and molecular study. (PubMed, Odontology) - "SFZN individually has significantly increased keratin thickness, disrupted Nrf2 machinery and glutathione tissue level, while SFZN in combination with ESOm showed significant increase in area% of iron deposition. DNA degradation using comet assay was evaluated using Kruskal-Wallis and Dunn's test which revealed no significant difference of tail length and tail moment in SFZN group and ESOm group but these parameters were significantly different in these two groups in relation to the control group (p < 0.05)."

Journal • Preclinical • Immunology • Renal Disease

Comparison of the effects of sulfasalazine and synbiotic treatments on the microbiota in a rat model of ulcerative colitis (ESCMID Global 2026) - No abstract available

Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The Impact of Active Transport on Rabbit Corneal Drug Permeability: utilizing the microflow-based PermeaSys device. (PubMed, Eur J Pharm Sci) - "The rabbit corneal permeability was first validated with three model compounds, rhodamine 123, benzoic acid, and paracellular marker compound lucifer yellow, before studying the permeability with three clinically used drugs, ciprofloxacin, diclofenac, and methotrexate...However, methotrexate permeability was altered when administrated together with sulfasalazine and MK-571, which can inhibit several known drug transporters. The data generated here with the PermeaSys instrument is comparable to studies conducted with the Ussing chamber and can be reliably used for the study of permeability and active transport in the cornea. However, active transport does not appear to have a great impact on the corneal permeability of the studied drug compounds."

Journal • Preclinical

All that aches is not psoriatic arthritis: Recognizing the co-existence of psoriasis and rheumatoid arthritis (AAD 2026) - "TNF-α inhibitors and methotrexate were the most commonly used systemic treatments, used in 21(65.6%) and 20 (62.5%) patients, respectively. Other systemic agents used included leflunomide (43.7%), hydroxychloroquine (40.6%), sulfasalazine (31.2%), abatacept (25%), Janus kinase inhibitors (18.75%), and tocilizumab (9.37%)...Two patients required additional systemic therapy for treatment of their psoriasis and were treated with guselkumab and apremilast. Two patients experienced psoriasis exacerbation with adalimumab. Patients with psoriasis may have co-existing seropositive rheumatoid arthritis, which has important implications for evaluation and treatment distinctive from psoriatic arthritis. Joint symptoms should prompt evaluation and consideration of a rheumatology referral, as treating rheumatoid arthritis can also improve psoriasis."

Dermatology • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy of Sulfasalazine in Patients with Primary Biliary Cholangitis and Incomplete Response to Ursodeoxycholic Acid (APASL 2026) - No abstract available

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. (PubMed, Ann Rheum Dis) - "These updated EULAR recommendations provide consensus on RA management based on currently available evidence regarding efficacy, safety, and cost."

Journal • Cardiovascular • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Adverse events related to drug-drug interactions in tocilizumab combination therapy: a retrospective analysis and clinical implications. (PubMed, Front Med (Lausanne)) - "The most significant DDI-related AEs identified for specific TCZ drug combinations were as follows: with DMARDs (e.g., methotrexate, hydroxychloroquine, and leflunomide), occurrence of anti-cyclic citrullinated peptide (CCP) positivity, hand deformity, and pemphigus were observed; with glucocorticoids (specifically prednisone), pemphigus, hand deformity, glossodynia, and pericarditis should be monitored; with NSAIDs (specifically diclofenac), heightened vigilance is warranted for anti-CCP positive, rheumatic fever, duodenal ulcer perforation, and Helicobacter infections. Age and sex influence DDI risks: adults (≥18 years) were more susceptible to infusion reactions with TCZ + hydroxychloroquine or TCZ + sulfasalazine, and to joint swelling with TCZ + naproxen. Male patients demonstrated a higher incidence of stomatitis with TCZ + methotrexate, and of joint swelling with TCZ + ibuprofen or TCZ + naproxen. Female patients were more susceptible to infusion-related reactions..."

Adverse events • Journal • Retrospective data • Cardiovascular • Dental Disorders • Immunology • Infectious Disease • Musculoskeletal Diseases • Peptic Ulcer • Rheumatology • Stomatitis

SAPHO Syndrome (AAD 2026) - "He was HLA-B27 positive and treated with sulfasalazine without relief, after which he was transitioned to an adalimumab biosimilar...Within two months, his folliculitis evolved into severe acne conglabata, requiring initiation of doxycycline...Importantly, it underscores that the clinical picture may evolve over months to years, with dermatologic features emerging after rheumatologic symptoms or vice versa. Recognition of this variability is critical to avoid misdiagnosis and to guide timely, individualized management."

Acne Vulgaris • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Rare Diseases

Liquiritigenin targets transferrin receptor to potentiate ferroptosis sensitivity in colorectal cancer cells. (PubMed, Phytomedicine) - "Our findings reveal a previously unrecognized role for LIQ as a ferroptosis sensitizer and highlight its translational potential as a dietary intervention in CRC therapy."

Journal • Colorectal Cancer • Oncology • Solid Tumor • Targeted Protein Degradation

Synergistic Effect of Rice Bran and Lactobacillus Ferulate Esterase on Dextran Sodium Sulfate (DSS)-Induced Ulcerative Colitis (UC) in Mice. (PubMed, Chem Biodivers) - "The animal groups were divided into control group (CON), DSS group (MOD), sulfasalazine group (SUL), rice bran group (RBN), L. johnsonii 46 group (LAJ), and LJRB treatment group (RBL)...Histopathological observations confirmed LJRB preserved colon tissue integrity, reduced goblet cell loss, and alleviated mucosal erosion and edema. Collectively, these findings demonstrate LJRB alleviates UC through multi-targeted mechanisms (anti-inflammation, antioxidation, SCFA production promotion, and nuclear factor kappa-B (NF-κB) pathway inhibition), highlighting its potential as a novel natural dietary supplement for UC prevention and management."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL10 • IL1B • IL6 • MYD88 • NFKBIA • TLR4 • TNFA • TRAF6

Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis. (PubMed, Semin Arthritis Rheum) - "Although most patients improved, especially with biologics, axial involvement, early diagnosis, and comorbidities were linked to greater disease burden and need for intensive therapy. Although about half of the patients initially responded to DMARDs, a substantial proportion required biologic therapy for sustained disease control. Therefore, earlier biologic treatment may be considered in patients with poor prognostic factors. BASDAI and JSpADA may be more suitable for monitoring ERA activity. Prospective multicenter studies are needed to confirm these findings and optimize treatment."

Journal • Idiopathic Arthritis • Immunology • Pediatrics • Rheumatology

SHIP: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (clinicaltrials.gov) - P2 | N=32 | Completed | Sponsor: Brigham and Women's Hospital | Recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Mar 2026 | Trial primary completion date: Sep 2024 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date

The Effect of Anti-TNF Group Drugs on Thyroid Function in Patients with ‎Rheumatoid Arthritis and Ankylosing Spondylitis. (PubMed, Iran J Immunol) - "Patients received either conventional treatment (DMARDs and NSAIDs/sulfasalazine) or anti-TNF agents...A significant TSH change was observed only in the RA-DMARD group (p < 0.05), while no significant changes in free T4 were detected in any group. Anti-TNF therapy showed no significant effect on thyroid function or autoimmune thyroid disease in patients with RA and AS during a six-month follow-up."

Journal • Ankylosing Spondylitis • Endocrine Disorders • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Multifunctional platinum(IV) complexes reverse cisplatin resistance in triple- negative breast cancer via ferroptosis and apoptosis. (PubMed, J Inorg Biochem) - "To address these limitations, a series of novel platinum(IV) complexes were designed by integrating ferroptosis inducers (sulfasalazine derivatives) with platinum-based moieties. Among them, complex 11 emerged as the most effective agent against both cisplatin (CDDP)-sensitive and CDDP-resistant TNBC cell lines, but showed lower cytotoxicity toward the normal breast epithelial cell line MCF-10 A compared with CDDP or carboplatin...In vivo, 11 exhibited potent antitumor efficacies without causing significant toxicity. Collectively, this study presents a promising strategy for TNBC treatment by integrating chemotherapy with ferroptosis within a single molecular entity."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • GPX4 • SLC7A11

Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study. (PubMed, Glob Heart) - "Genetic instruments were employed to proxy the pharmacological effects of seven DMARD classes, including sulfasalazine, cyclosporine, leflunomide, IL-6 inhibitors, TNF-alpha inhibitors, abatacept, rituximab, and JAK inhibitors. Overall, this study presents evidence supporting a causal association between DMARDs and several CVDs. Nevertheless, further clinical investigations are necessary to validate our findings."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Inflammation • Ischemic stroke • Myocardial Infarction • CD80 • IL6R • RELA

BIO3: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (clinicaltrials.gov) - P4 | N=286 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Mar 2022 ➔ Mar 2025 | Trial primary completion date: Mar 2022 ➔ Mar 2025

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

BIO3: Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients with Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (clinicaltrials.gov) - P4 | N=286 | Recruiting | Sponsor: University Hospital, Strasbourg, France | Trial completion date: Mar 2025 ➔ Mar 2029 | Trial primary completion date: Mar 2025 ➔ Mar 2029

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Rituximab for active Rhupus syndrome with severe thrombocytopenia after multiple DMARD failures: a case report (LUPUS 2026) - "Management included MTX 25 mg weekly (since 2010), leflunomide (2014–2018, leukopenia), sulfasalazine 2 g/day (2018–2020, leukopenia), hydroxychloroquine (since 2018), intermittent glucocorticoid tapers, and biologics—tocilizumab 162 mg weekly (2021–2024, inadequate response) and upadacitinib 15 mg/day (stopped July 2025 for thrombocytopenia).During hospitalization in the rheumatology clinic, physical examination showed a positive squeeze test at PIP3 and MCP1–3 of the right hand and MCP1–2 of the left hand. Treatment was well tolerated.Abstract PO:04:106 Figure 1 Conclusions Cytopenias are common in Rhupus/SLE and may be more pronounced in Asian populations. This case supports the potential role of rituximab in Rhupus complicated by severe thrombocytopenia, demonstrating prompt clinical and laboratory responses after failure of multiple DMARDs/biologics."

Case report • Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis

DRESS Syndrome and Liver Injury in a US Healthcare System (AAAAI 2026) - "Among those with one attributed drug (n=28), the most frequently implicated were vancomycin (n=10), lamotrigine (n=5), sulfasalazine (n=3), and ceftriaxone (n=3). Conclusions Most DRESS patients had acute liver injury as a manifestation of DRESS, but few had significant sequelae that occurred during acute DRESS or in the immediate recovery period. Persistent liver injury was not identified."

Eosinophilia • Hepatology • Liver Failure

Oral soft tissue manifestations in patients with rheumatoid arthritis undergoing antirheumatic therapy: a scoping review. (PubMed, Odontology) - "Methotrexate was the most frequently used agent, followed by leflunomide, sulfasalazine, hydroxychloroquine, and corticosteroids. In summary, oral manifestations represent clinically relevant yet underrecognized adverse effects of antirheumatic therapy in RA. Strengthening collaboration between rheumatologists and oral medicine specialists is crucial for early recognition, accurate differential diagnosis, and prevention of severe outcomes."

Journal • Review • Dental Disorders • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Stomatitis • Xerostomia

Natural Antioxidant Lipoic Acid Constructed Nanodrug for Oral Therapy of Inflammatory Bowel Disease. (PubMed, ACS Nano) - "In vivo results demonstrated that cLAPs mediated a 75.9% recovery of body weight and a 94.4% recovery of colon length in IBD mice, representing 1.4-fold and 1.6-fold greater efficacy than that achieved by a 5-fold higher dose of sulfasalazine (53.3% and 58.3%, respectively). The natural antioxidant-based nanodrug holds potential in clinic."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Potential of pharmacogenetics in treatment of chronic inflammatory diseases - a danish report overview from 2000 - 2024. (PubMed, Pharmacogenomics J) - "Of the most used drugs Azathioprine, Mesalazine, and Sulfasalazine have pharmacogenetic recommendation guidelines and/or FDA annotations. Up to 13,934 Danish individuals using infliximab or adalimumab (~580 individuals each year) have a potential risk of developing immunogenicity related to monoclonal antibodies. This study shows the possibilities of pharmacogenetic testing as a supportive clinical decision tool to optimize treatment and minimize risk of e.g., serious adverse effects, remission, and other serious complications."

Biomarker • Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Therapeutic Effects of Pistacia terebinthus L. (Terebinth) Fruit on Ulcerative Colitis: In Vitro Antioxidant and Anti-Inflammatory Activities, In Vivo Histopathological-Biochemical Evaluation, and LC-HR/MS-Based Phenolic Profiling. (PubMed, J Ethnopharmacol) - "P. terebinthus fruit extract exerted dose-dependent protective and therapeutic effects against acetic acid-induced ulcerative colitis by modulating inflammatory mediators and oxidative stress. These findings support its potential as a natural therapeutic candidate for managing inflammatory bowel diseases."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL1B • IL6 • TNFA

Evaluating Therapeutic Efficacy of SCL7A11 and GLUT1 Inhibition in Triple-Negative Breast Cancer via a GSH/ATP Dual-NIR-Responsive Fluorogenic Sensor. (PubMed, Anal Chem) - "We constructed the first near-infrared dual-activation probe M1219, which successfully visualized the regulatory relationship between oxidative stress and energy imbalance under the stimulation of sulfasalazine (SAS, SLC7A11 inhibitor) and rapamycin A (RgA, GLUT1 inhibitor) by real-time monitoring of the dynamic changes of GSH/ATP in cells. For the first time, we elucidated the NADPH/G6PD/GPX4/ACSL4 axis-mediated metabolic regulatory network under dual-target inhibition. Leveraging the tumor microenvironment's GSH/ATP-specific activation mechanism, M1219 achieved the in vivo visualization of therapeutic efficacy in TNBC mice, validated the enhanced antitumor effect of the combined inhibition strategy, enabled precise resection of TNBC infiltration boundaries (negative margin of <0.1 mm), and successfully distinguished tumor tissue from marginal tissue in clinically resected breast cancer specimens."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ACSL4 • GPX4 • SLC2A1 • SLC7A11